| 翻訳と辞書 |
| Martin Shkreli ： ウィキペディア英語版 |
Martin Shkreli
Martin Shkreli (born April 1, 1983)〔 is an American hedge fund manager and entrepreneur, specializing in healthcare businesses, and is a co-founder of MSMB Capital Management and the founder of Turing Pharmaceuticals AG. He is a co-founder and was the chief executive officer of Retrophin LLC, a biotechnology firm founded in 2011. In September 2015, Shkreli was criticized when Turing Pharmaceuticals obtained the manufacturing license for Daraprim, and raised its price by 5,455 percent (from $13.50 to $750 per tablet). After initially defending the price increase, Shkreli said an unspecified lower price would be established. Turing Pharmaceuticals announced on November 24, 2015 "that it would not reduce the list price of that drug after all" but they will offer various patient assistance programs.
== Early life ==
Shkreli, the son of Albanian and Croatian immigrants, was born in Brooklyn, New York. Shkreli has two sisters and one brother. He grew up in a working-class community in Brooklyn. Shkreli skipped several grades in school and received a degree in business from New York's Baruch College in 2004.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Martin Shkreli」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|